{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T19:46:15Z","timestamp":1791229575013,"version":"4.1.0"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,9,27]],"date-time":"2022-09-27T00:00:00Z","timestamp":1664236800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,9,27]],"date-time":"2022-09-27T00:00:00Z","timestamp":1664236800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Precision medicine highlights the importance of incorporating molecular genetic testing into standard clinical care. Next-generation sequencing can detect cancer-specific gene mutations, and molecular-targeted drugs can be designed to be effective for one or more specific gene mutations. For patients with special site metastases, it is particularly important to use appropriate samples for genetic profiling. This study aimed to determine whether genomic profiling using ASC and PE is effective in detecting genetic mutations.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>Tissues, plasma, ascites (ASC) supernatants, and pleural effusion (PE) samples from gastrointestinal cancer patients with peritoneal metastasis and lung cancer patients with pleural metastasis were collected for comprehensive genomic profiling. The samples were subjected to next-generation sequencing using a panel of 59 or 1021 cancer-relevant genes panel.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>A total of 156 tissues, 188 plasma samples, 45 ASC supernatants, and 1 PE samples from 304 gastrointestinal cancer patients and 446 PE supernatants, 122 tissues, 389 plasma samples, and 45 PE sediments from 407 lung cancer patients were analyzed. The MSAF was significantly higher in ASC and PE supernatant than that in plasma ctDNA (50.00% vs. 3.00%, <jats:italic>p<\/jats:italic>\u2009&lt;\u20090.0001 and 28.5% vs. 1.30%, <jats:italic>p<\/jats:italic>\u2009&lt;\u20090.0001, respectively). The ASC supernatant had a higher actionable mutation rate and more actionable alterations than the plasma ctDNA in 26 paired samples. The PE supernatant had a higher total actionable mutation rate than plasma (80.3% vs. 48.4%, <jats:italic>p<\/jats:italic>\u2009&lt;\u20090.05). The PE supernatant had a higher frequency of uncommon variations than the plasma regardless of distant organ metastasis.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>ASC and PE supernatants could be better alternative samples when tumor tissues are not available, especially in patients with only peritoneal or pleural metastases.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12885-022-09922-5","type":"journal-article","created":{"date-parts":[[2022,9,27]],"date-time":"2022-09-27T09:03:17Z","timestamp":1664269397000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":25,"title":["Liquid biopsy using ascitic fluid and pleural effusion supernatants for genomic profiling in gastrointestinal and lung cancers"],"prefix":"10.1186","volume":"22","author":[{"given":"Huita","family":"Wu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haonan","family":"Ji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenhui","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yifang","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bangkai","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiayin","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rongrong","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuan","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,9,27]]},"reference":[{"issue":"8","key":"9922_CR1","doi-asserted-by":"publisher","first-page":"472","DOI":"10.1038\/nrclinonc.2013.110","volume":"10","author":"E Crowley","year":"2013","unstructured":"Crowley E, Di Nicolantonio F, Loupakis F, Bardelli A. Liquid biopsy: monitoring cancer-genetics in the blood. Nat Rev Clin Oncol. 2013;10(8):472\u201384.","journal-title":"Nat Rev Clin Oncol"},{"key":"9922_CR2","unstructured":"Bettegowda C, Sausen M, Leary RJ, Kinde I, Wang Y, Agrawal N, Bartlett BR, Wang H, Luber B, Alani RM et al: Detection of circulating tumor DNA in early- and late-stage human malignancies. Science translational medicine 2014\u00a0;6(224):224ra224."},{"issue":"6","key":"9922_CR3","doi-asserted-by":"publisher","first-page":"650","DOI":"10.1158\/2159-8290.CD-13-1014","volume":"4","author":"DA Haber","year":"2014","unstructured":"Haber DA, Velculescu VE. Blood-based analyses of cancer: circulating tumor cells and circulating tumor DNA. Cancer Discov. 2014;4(6):650\u201361.","journal-title":"Cancer Discov"},{"issue":"5","key":"9922_CR4","doi-asserted-by":"publisher","first-page":"948","DOI":"10.1158\/1535-7163.MCT-16-0436","volume":"16","author":"H Husain","year":"2017","unstructured":"Husain H, Nykin D, Bui N, Quan D, Gomez G, Woodward B, Venkatapathy S, Duttagupta R, Fung E, Lippman SM, et al. Cell-Free DNA from Ascites and Pleural Effusions: Molecular Insights into Genomic Aberrations and Disease Biology. Mol Cancer Ther. 2017;16(5):948\u201355.","journal-title":"Mol Cancer Ther"},{"issue":"1","key":"9922_CR5","doi-asserted-by":"publisher","first-page":"149","DOI":"10.21037\/tcr.2017.01.13","volume":"6","author":"J Wei","year":"2017","unstructured":"Wei J, Yang Y, Du J, Zou Z, Zhang Y, Wu N, Wang Q, Yuan L, Liu B. Peritoneal metastasis in relation to outcome and therapeutic strategy in gastric cancer. TRANSLATIONAL CANCER RESEARCH. 2017;6(1):149\u201356.","journal-title":"TRANSLATIONAL CANCER RESEARCH"},{"issue":"27","key":"9922_CR6","doi-asserted-by":"publisher","first-page":"3484","DOI":"10.3748\/wjg.v25.i27.3484","volume":"25","author":"JM S\u00e1nchez-Hidalgo","year":"2019","unstructured":"S\u00e1nchez-Hidalgo JM, Rodr\u00edguez-Ortiz L, Arjona-S\u00e1nchez \u00c1, Rufi\u00e1n-Pe\u00f1a S, Casado-Adam \u00c1, Cosano-\u00c1lvarez A, Brice\u00f1o-Delgado J. Colorectal peritoneal metastases: Optimal management review. World J Gastroenterol. 2019;25(27):3484.","journal-title":"World J Gastroenterol"},{"key":"9922_CR7","doi-asserted-by":"crossref","unstructured":"Yablonskii P, Nefedov A, Arseniev A, Kozak A, Mortada M, Patsyuk A: Non-small cell lung cancer, pleural effusion and carcinomatosis: always a criterion of inoperability? AME Medical Journal 2020, 5.","DOI":"10.21037\/amj.2020.02.07"},{"issue":"3","key":"9922_CR8","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1136\/jclinpath-2019-206127","volume":"73","author":"C Fumagalli","year":"2020","unstructured":"Fumagalli C, Rappa A, Casadio C, Betella I, Colombo N, Barberis M, Guerini-Rocco E. Next-generation sequencing-based BRCA testing on cytological specimens from ovarian cancer ascites reveals high concordance with tumour tissue analysis. J Clin Pathol. 2020;73(3):168\u201371.","journal-title":"J Clin Pathol"},{"issue":"19","key":"9922_CR9","doi-asserted-by":"publisher","first-page":"5532","DOI":"10.7150\/thno.34070","volume":"9","author":"L Tong","year":"2019","unstructured":"Tong L, Ding N, Tong X, Li J, Zhang Y, Wang X, Xu X, Ye M, Li C, Wu X. Tumor-derived DNA from pleural effusion supernatant as a promising alternative to tumor tissue in genomic profiling of advanced lung cancer. Theranostics. 2019;9(19):5532.","journal-title":"Theranostics"},{"key":"9922_CR10","first-page":"337","volume":"11","author":"H Yang","year":"2021","unstructured":"Yang H, Wang Y, Jia Z, Wang Y, Yang X, Wu P, Song Y, Xu H, Gu D, Chen R. Characteristics of T-Cell Receptor Repertoire and Correlation With EGFR Mutations in All Stages of Lung Cancer. Front Oncol. 2021;11:337.","journal-title":"Front Oncol"},{"key":"9922_CR11","doi-asserted-by":"crossref","unstructured":"Zhuo M, Guan Y, Yang X, Hong L, Wang Y, Li Z, Chen R, Abbas H, Chang L, Gong Y et al: The prognostic and therapeutic role of genomic subtyping by sequencing tumor or cell-free DNA in pulmonary large-cell neuroendocrine carcinoma. Clinical cancer research : an official journal of the American Association for Cancer Research 2019.","DOI":"10.1158\/1078-0432.CCR-19-0556"},{"key":"9922_CR12","doi-asserted-by":"publisher","first-page":"550","DOI":"10.3389\/fonc.2019.00550","volume":"9","author":"S Sun","year":"2019","unstructured":"Sun S, Liu Y, Eisfeld AK, Zhen F, Jin S, Gao W, Yu T, Chen L, Wang W, Chen W, et al. Identification of Germline Mismatch Repair Gene Mutations in Lung Cancer Patients With Paired Tumor-Normal Next Generation Sequencing: A Retrospective Study. Front Oncol. 2019;9:550.","journal-title":"Front Oncol"},{"issue":"5","key":"9922_CR13","doi-asserted-by":"publisher","first-page":"1359","DOI":"10.1002\/ijc.32536","volume":"146","author":"F Ma","year":"2020","unstructured":"Ma F, Guan Y, Yi Z, Chang L, Li Q, Chen S, Zhu W, Guan X, Li C, Qian H. Assessing tumor heterogeneity using ctDNA to predict and monitor therapeutic response in metastatic breast cancer. Int J Cancer. 2020;146(5):1359\u201368.","journal-title":"Int J Cancer"},{"issue":"4","key":"9922_CR14","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1016\/j.jmoldx.2017.04.007","volume":"19","author":"X Yang","year":"2017","unstructured":"Yang X, Chu Y, Zhang R, Han Y, Zhang L, Fu Y, Li D, Peng R, Li D, Ding J. Technical validation of a next-generation sequencing assay for detecting clinically relevant levels of breast cancer\u2013related single-nucleotide variants and copy number variants using simulated cell-free DNA. J Mol Diagn. 2017;19(4):525\u201336.","journal-title":"J Mol Diagn"},{"issue":"10","key":"9922_CR15","doi-asserted-by":"publisher","first-page":"1307","DOI":"10.1093\/bioinformatics\/bts146","volume":"28","author":"J Li","year":"2012","unstructured":"Li J, Lupat R, Amarasinghe KC, Thompson ER, Doyle MA, Ryland GL, Tothill RW, Halgamuge SK, Campbell IG, Gorringe KL. CONTRA: copy number analysis for targeted resequencing. Bioinformatics. 2012;28(10):1307\u201313.","journal-title":"Bioinformatics"},{"key":"9922_CR16","doi-asserted-by":"publisher","first-page":"7","DOI":"10.20517\/2394-4722.2017.67","volume":"4","author":"PH Sugarbaker","year":"2018","unstructured":"Sugarbaker PH. Gastric cancer: prevention and treatment of peritoneal metastases. J Cancer Metastasis Treat. 2018;4:7.","journal-title":"J Cancer Metastasis Treat"},{"key":"9922_CR17","doi-asserted-by":"crossref","unstructured":"Medenica M, Medenica M, Cosovic D: Pleural Effusions in Lung Cancer: Detection and Treatment. Lung Cancer: Strategies for Diagnosis and Treatment 2018:43.","DOI":"10.5772\/intechopen.78307"},{"issue":"1","key":"9922_CR18","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1080\/15384047.2018.1504720","volume":"20","author":"S Zhou","year":"2019","unstructured":"Zhou S, Xu B, Qi L, Zhu D, Liu B, Wei J. Next-generation sequencing reveals mutational accordance between cell-free DNA from plasma, malignant pleural effusion and ascites and directs targeted therapy in a gastric cancer patient. Cancer Biol Ther. 2019;20(1):15\u201320.","journal-title":"Cancer Biol Ther"},{"issue":"19","key":"9922_CR19","doi-asserted-by":"publisher","first-page":"1998","DOI":"10.1001\/jama.2014.3741","volume":"311","author":"MG Kris","year":"2014","unstructured":"Kris MG, Johnson BE, Berry LD, Kwiatkowski DJ, Iafrate AJ, Wistuba II, Varella-Garcia M, Franklin WA, Aronson SL, Su P-F. Using multiplexed assays of oncogenic drivers in lung cancers to select targeted drugs. JAMA. 2014;311(19):1998\u20132006.","journal-title":"JAMA"},{"issue":"10","key":"9922_CR20","doi-asserted-by":"publisher","first-page":"1296","DOI":"10.1016\/S1470-2045(20)30444-7","volume":"21","author":"NC Turner","year":"2020","unstructured":"Turner NC, Kingston B, Kilburn LS, Kernaghan S, Wardley AM, Macpherson IR, Baird RD, Roylance R, Stephens P, Oikonomidou O. Circulating tumour DNA analysis to direct therapy in advanced breast cancer (plasmaMATCH): a multicentre, multicohort, phase 2a, platform trial. Lancet Oncol. 2020;21(10):1296\u2013308.","journal-title":"Lancet Oncol"},{"issue":"7","key":"9922_CR21","doi-asserted-by":"publisher","first-page":"1053","DOI":"10.1038\/s41379-019-0212-1","volume":"32","author":"J Wang","year":"2019","unstructured":"Wang J, Yi Y, Xiao Y, Dong L, Liang L, Teng L, Ying JM, Lu T, Liu Y, Guan Y. Prevalence of recurrent oncogenic fusion in mismatch repair-deficient colorectal carcinoma with hypermethylated MLH1 and wild-type BRAF and KRAS. Mod Pathol. 2019;32(7):1053\u201364.","journal-title":"Mod Pathol"},{"key":"9922_CR22","doi-asserted-by":"crossref","unstructured":"Lee SJ, Hong JY, Kim K, Kim K-M, Kang SY, Lee T, Kim ST, Park SH, Park YS, Lim HY: Detection of Fusion Genes Using a Targeted RNA Sequencing Panel in Gastrointestinal and Rare Cancers. Journal of Oncology 2020, 2020.","DOI":"10.1155\/2020\/4659062"},{"issue":"12","key":"9922_CR23","doi-asserted-by":"publisher","first-page":"1730","DOI":"10.1038\/bjc.2015.401","volume":"113","author":"A Amatu","year":"2015","unstructured":"Amatu A, Somaschini A, Cerea G, Bosotti R, Valtorta E, Buonandi P, Marrapese G, Veronese S, Luo D, Hornby Z. Novel CAD-ALK gene rearrangement is drugable by entrectinib in colorectal cancer. Br J Cancer. 2015;113(12):1730\u20134.","journal-title":"Br J Cancer"},{"issue":"15","key":"9922_CR24","doi-asserted-by":"publisher","first-page":"3831","DOI":"10.1158\/1078-0432.CCR-15-3000","volume":"22","author":"E Yakirevich","year":"2016","unstructured":"Yakirevich E, Resnick MB, Mangray S, Wheeler M, Jackson CL, Lombardo KA, Lee J, Kim K-M, Gill AJ, Wang K. Oncogenic ALK fusion in rare and aggressive subtype of colorectal adenocarcinoma as a potential therapeutic target. Clin Cancer Res. 2016;22(15):3831\u201340.","journal-title":"Clin Cancer Res"},{"issue":"4","key":"9922_CR25","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1056\/NEJMoa1817323","volume":"381","author":"Y Loriot","year":"2019","unstructured":"Loriot Y, Necchi A, Park SH, Garcia-Donas J, Huddart R, Burgess E, Fleming M, Rezazadeh A, Mellado B, Varlamov S. Erdafitinib in locally advanced or metastatic urothelial carcinoma. N Engl J Med. 2019;381(4):338\u201348.","journal-title":"N Engl J Med"},{"key":"9922_CR26","doi-asserted-by":"crossref","unstructured":"Abou-Alfa GK, Sahai V, Hollebecque A, Vaccaro G, Melisi D, Al-Rajabi R, Paulson AS, Borad MJ, Gallinson D, Murphy AG: Pemigatinib for previously treated, locally advanced or metastatic cholangiocarcinoma: a multicentre, open-label, phase 2 study. The Lancet Oncology 2020.","DOI":"10.2139\/ssrn.3489302"},{"issue":"9","key":"9922_CR27","doi-asserted-by":"publisher","first-page":"813","DOI":"10.1056\/NEJMoa2005653","volume":"383","author":"A Drilon","year":"2020","unstructured":"Drilon A, Oxnard GR, Tan DS, Loong HH, Johnson M, Gainor J, McCoach CE, Gautschi O, Besse B, Cho BC. Efficacy of selpercatinib in RET fusion\u2013positive non\u2013small-cell lung cancer. N Engl J Med. 2020;383(9):813\u201324.","journal-title":"N Engl J Med"},{"key":"9922_CR28","doi-asserted-by":"crossref","unstructured":"Subbiah V, Hu MI-N, Gainor JF, Mansfield AS, Alonso G, Taylor MH, Zhu VW, Lopez PG, Amatu A, Doebele RC: Clinical activity of the RET inhibitor pralsetinib (BLU-667) in patients with RET fusion+ solid tumors. J Clin Oncol 2020, 38(15_suppl):109.","DOI":"10.1200\/JCO.2020.38.15_suppl.109"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-022-09922-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12885-022-09922-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-022-09922-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,9,27]],"date-time":"2022-09-27T09:05:33Z","timestamp":1664269533000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmccancer.biomedcentral.com\/articles\/10.1186\/s12885-022-09922-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9,27]]},"references-count":28,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["9922"],"URL":"https:\/\/doi.org\/10.1186\/s12885-022-09922-5","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,9,27]]},"assertion":[{"value":"8 October 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 July 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 September 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was conducted in accordance with the Declaration of Helsinki (as revised in 2013) and approved by the ethics committee of Zhongshan Hospital, Xiamen University(xmzsyyky2021-012), and all patients provided informed written consents. All patients who used tissue and medical data in this study provided written informed consent in accordance with the Helsinki Declaration.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors report no conflicts of interest in this work.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"1020"}}